Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05220774
Other study ID # REB21-1887
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2018
Est. completion date November 30, 2023

Study information

Verified date December 2023
Source University of Calgary
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Studies directly comparing EDCS with AAS during ERCP are scarce, varying widely in their designs and reaching conflicting conclusions regarding safety and effectiveness. The investigators will assess, via a multi-center prospective study, the success, adverse event rates, and patient tolerability of ERCP when performed under AAS versus EDCS.


Description:

1. Background and Rationale Endoscopic retrograde cholangiopancreatography (ERCP) is critical in the diagnosis and therapy of pancreatico-biliary conditions. In contrast to routine upper and lower gastrointestinal (GI) endoscopic procedures, ERCP has several unique characteristics that require consideration when formulating a sedation plan. Factors such as patient comorbidities, positioning, airway issues, and longer procedure times collectively contribute to a high risk of sedation-related adverse events (SRAEs) during ERCP. In contrast to the United States (US), where anesthetist-administered sedation (AAS) for ERCP is the norm, endoscopist-directed conscious sedation (EDCS) remains the primary method of sedation for ERCP in the United Kingdom (UK), Canada, and other countries with publicly funded national healthcare systems. This practice is largely driven by resource availability and cost limitations. AAS typically involves either general endotracheal anesthesia (GEA) or deep sedation without an endotracheal tube, often referred to as monitored anesthesia care (MAC). Studies directly comparing EDCS with AAS during ERCP are scarce, varying widely in their designs and reaching conflicting conclusions regarding safety and effectiveness. Furthermore, little is known regarding the sedation method as it relates to procedure-related adverse events (AEs). Finally, patient-reported experience measures (PREMs) in this field have been insufficiently studied to date. The heterogenous nature and inconsistent findings of existing studies comparing AAS and EDCS necessitate further study with data of higher quality and granularity. 2. Research Question and Objectives The investigators will assess, via a multi-center prospective study, the success, adverse event rates, and patient tolerability of ERCP when performed under AAS versus EDCS. 3. Methods A total of 9 sites will participate using data from the Calgary Registry for Advanced and Therapeutic Endoscopy (CReATE). An anticipated 85% of procedures across included sites will be performed under EDCS, with the remainder performed under AAS. Consecutive patients ≥ 18 years of age undergoing ERCP will be included if informed consent is obtained. The investigators will collect information on 1) patient demographics and risk factors (including but not limited to Sphincter of Oddi dysfunction, prior acute or recurrent pancreatitis, and relevant medications) and 2) procedural details (including but not limited to cannulation attempts, cannulation time, trainee involvement and post-ERCP pancreatitis [PEP] prophylaxis). At the time of discharge from the endoscopy unit, outpatients will be assessed using the Patient-reported Scale for Tolerability of Endoscopic Procedures (PRO-STEP), a validated tool that measures intra- and post-procedural physical tolerability. Thirty days after index ERCPs, research staff will contact patients using standardized interview scripts in addition to performing electronic medical record reviews to assess for any adverse events, defined using the American Society for Gastrointestinal Endoscopy (ASGE) Lexicon. The primary outcome will be the procedural success of ERCP, defined using a previously published set of a priori criteria. Secondary outcomes will include immediate and delayed adverse event rates (including SRAEs, PEP, clinically significant bleeding, and cholangitis/sepsis), patient tolerability (as assessed by PRO-STEP), total cannulation attempts, pancreatic duct (PD) cannulation, rates of pre-cut sphincterotomy or needle-knife papillotomy (NKP), cannulation time, and overall procedure time (from esophageal intubation to extubation). SRAEs will be defined as any of the following: oxygen saturation < 85% for a sustained period of 60 seconds, requirement for mask ventilation or unplanned endotracheal intubation, intraprocedural use of one or more vasopressors or reversal agent(s), hypotension with systolic blood pressure < 90 mm Hg requiring treatment, cardiac and/or respiratory arrest, or death. PRO-STEP scores of >6 (on a scale of 0-10) will be considered to represent poor intraprocedural tolerability.


Recruitment information / eligibility

Status Completed
Enrollment 3174
Est. completion date November 30, 2023
Est. primary completion date August 30, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject referred for ERCP for biliary indication; - Subject has not undergone prior ERCP, sphincterotomy, and/or sphincteroplasty; - Subject age 18 years or older; - Subject able to give informed consent to involvement be included. Exclusion Criteria: - Subject has a standard contraindication to ERCP; - Subject or surrogate unable or unwilling to provide informed consent; - Subject age < 18 years; - Pancreatic indication for ERCP; - Morbid obesity; - Known history of difficult sedation and/or failed medical procedure(s), endoscopy or other, using EDCS; - Planned cholangioscopy.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Canada Peter Lougheed Hospital Calgary Alberta

Sponsors (7)

Lead Sponsor Collaborator
University of Calgary Halton Health (Oakville), Island Health, Victoria, BC, McGill University, Queen's University, Radboud Medical Center, University of Ottawa

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary procedural success of ERCP Defined using a previously published set of a priori criteria by indication (Forbes et al. BMC Gastroenterology 2020; 20:64). 1 day
Secondary post-ERCP pancreatitis Defined using a previously published set of a priori criteria by indication (Cotton et al. Gastrointest Endoscopy 2010; 71:446-54). 30 days
Secondary post-ERCP bleeding Defined using a previously published set of a priori criteria by indication (Cotton et al. Gastrointest Endoscopy 2010; 71:446-54). 30 days
Secondary post-ERCP cholangitis Defined using a previously published set of a priori criteria by indication (Cotton et al. Gastrointest Endoscopy 2010; 71:446-54). 30 days
Secondary patient tolerability Defined on patient-reported scale for tolerability of endoscopic procedures (PRO-STEP) - Forbes et al. Gastrointest Endosc 2021; 94: 103-10 - measured from 0 to 10 in all domains. 1 day
See also
  Status Clinical Trial Phase
Completed NCT02041390 - Effect of Short Message Service Intervention on Stent Removal/Exchange Adherence in Patients With Benign Pancreaticobiliary Diseases N/A
Completed NCT04619511 - Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
Terminated NCT00419549 - Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP) Phase 2/Phase 3
Recruiting NCT04255095 - Early Intervention of High Tension in the Pancreatic Duct on the Outcome of Severe Biliary Pancreatitis N/A
Completed NCT03698266 - Is Needle Knife Fistulotomy An Effective First Step Strategy For All ERCPs? N/A
Recruiting NCT03350555 - Clinical Trials to Validate the Use of Additioned Endoscopy in Endoscopic Retrograde Cholangiopancreatography N/A
Completed NCT04671095 - Single Use ERCP Performance -SURE Study
Recruiting NCT05603702 - STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis Phase 1
Recruiting NCT04447976 - Prospective Evaluation of Performance of Disposable Elevator Cap Duodenoscope During ERCP in Clinical Practice
Completed NCT03185390 - Periampullary Lesions Via ERCP in Assuit University Hospital N/A
Enrolling by invitation NCT03416205 - A Prospective Study of Treating Duodenal Papillary Sphincter in Different Ways During ERCP N/A
Recruiting NCT05211206 - IV Fluids and Post-ERCP Pancreatitis
Not yet recruiting NCT04658212 - A Multicenter Randomized Controlled Study of 3D Laparoscopy Versus Endoscopy in the Treatment of Choledocholithiasis N/A
Recruiting NCT04661332 - Registry of Endoscopic Retrograde Cholangiopancreatographies Performed in Humans
Terminated NCT02046590 - RCT of Efficacy and Safety of Sedation Compared to General Anesthesia for ERCP N/A
Recruiting NCT05219123 - Guidewire Management in ERCP
Completed NCT00731198 - Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP) Phase 3
Completed NCT04167592 - Benzydamine Hydrochloride Gargle in Reducing Propofol for ERCP N/A
Completed NCT01873079 - PPI for Prevention of Post-sphincterotomy Bleeding Phase 3
Not yet recruiting NCT05225909 - aScope Single Use ERCP Study- ASSURE Study